High-Level Overview
Manifold is an AI-powered clinical and life sciences research platform that accelerates biomedical R&D by automating the data-heavy, manual workflows that slow down modern research. The company builds a secure, scalable infrastructure that streamlines data collection, harmonization, governance, and analysis—turning what used to take months into insights generated in minutes. Its platform is designed specifically for complex, data-intensive research environments like cancer centers, population cohort studies, and omics-driven discovery.
Manifold serves leading academic medical centers, comprehensive cancer centers, and large-scale research organizations that struggle with fragmented data, legacy tools (like spreadsheets), and inefficient collaboration. It solves the systemic problem of brilliant scientists spending more time wrangling data than doing science. With $15 million in Series A funding in 2024 and a strategic collaboration with the Broad Institute of MIT and Harvard in early 2025, Manifold is gaining strong momentum as a next-generation research infrastructure provider in digital health and AI-driven life sciences.
---
Origin Story
Manifold was founded in 2016 in Newton, Massachusetts by four friends—Sourav Dey, Vivek Mohta, Rajendra Koppula, and Vinay Seth Mohta—as an AI lab focused on helping life sciences organizations move AI R&D projects into production. The founders, all with deep technical and AI/ML backgrounds, repeatedly observed a common pattern: world-class scientists were drowning in data complexity, forced to act like software engineers instead of biologists or clinicians. The problem wasn’t a lack of data or talent—it was the absence of a robust, intuitive data and AI foundation tailored to biomedical research.
This insight led to a pivotal shift in 2022: rather than building bespoke AI solutions for each client, the team decided to build a unified AI-powered research platform from the ground up. That platform became Manifold’s core product—an infrastructure layer that abstracts away the technical complexity of data pipelines, cohort building, and analysis so researchers can focus on discovery. Vinay Seth Mohta, who previously co-founded and served as CTO of Kyruus Health (a leading enterprise care access platform), brought operational and product leadership to scale this vision into a company trusted by top-tier research institutions.
---
Core Differentiators
AI-Native Research Infrastructure
- Built from the ground up as an AI-powered platform, not a legacy system retrofitted with AI features.
- Automates up to 80% of the “undifferentiated heavy lifting” in R&D: data cleaning, pipeline debugging, format harmonization, and cohort creation.
- Turns months-long analysis cycles into minutes, accelerating time to insight by orders of magnitude.
Designed for Biomedical Complexity
- Handles diverse, high-volume data types common in life sciences: EHRs, genomics, imaging, wearables, and longitudinal cohort data.
- Supports omics processing workflows, secure cohort studies, and multi-site collaborations with strong data governance and compliance.
- Enables “bring your own cloud” (BYOC) deployment, giving large institutions control over data residency and security.
Workflow Modernization for Research Teams
- Replaces error-prone spreadsheets and siloed tools with a unified, collaborative environment for study and data management.
- Reduces administrative burden and operational friction, allowing smaller teams to run larger, more sophisticated studies.
- Designed to make life sciences data and tools feel as intuitive as “a conversation with an expert colleague.”
Strategic Partnerships & Ecosystem
- Deep collaboration with the Broad Institute to co-develop a next-generation, AI-enabled life sciences research platform that extends the principles of Terra.
- Trusted by major research organizations including the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and the Morehouse School of Medicine.
- Positioned as a foundational layer that integrates with and enhances existing research ecosystems, rather than replacing them entirely.
---
Role in the Broader Tech Landscape
Manifold sits at the intersection of three powerful trends: the explosion of biomedical data, the maturation of AI/ML in life sciences, and the urgent need to modernize research infrastructure. As omics, real-world data, and digital biomarkers become central to drug discovery and precision medicine, traditional tools like Excel and custom scripts are no longer tenable. At the same time, AI is unlocking new possibilities in target discovery, patient stratification, and trial design—but only if researchers can access and analyze data quickly and securely.
The timing is critical: research organizations are under pressure to do more with constrained budgets, while regulators and funders increasingly demand reproducibility, transparency, and scalability. Manifold addresses this by providing a standardized, AI-powered “operating system” for research that reduces cost, accelerates timelines, and improves data quality. By lowering the technical barrier to advanced analytics, it also democratizes access to cutting-edge methods, enabling more institutions—especially those without large engineering teams—to participate in high-impact science.
In the broader ecosystem, Manifold is helping to redefine what’s possible in clinical and translational research. Its collaboration with the Broad Institute signals a shift toward open, interoperable, cloud-native platforms that support global collaboration and secure data sharing. This positions Manifold not just as a software vendor, but as a key enabler of the next generation of biomedical discovery.
---
Quick Take & Future Outlook
Manifold is poised to become a foundational layer in modern life sciences R&D, much like Snowflake or Databricks in enterprise data, but tailored specifically for the unique demands of biomedical research. Its bold vision—to make research ten times faster and one-tenth the cost—is ambitious, but its early traction with elite institutions and its deep technical pedigree suggest it’s on a credible path.
Looking ahead, Manifold will likely expand its footprint across academic medical centers, pharma R&D, and large population health initiatives. As AI models become more sophisticated and multimodal (e.g., combining genomics, imaging, and EHR data), the value of a unified, AI-native data platform will only grow. The company may also move further up the stack, offering pre-built AI workflows, trial design assistants, or even decision-support tools for clinical research operations.
In a world where breakthroughs in cancer, neurodegeneration, and precision medicine depend on how fast and well we can learn from data, Manifold’s mission—to free scientists from data drudgery and let them focus on discovery—could have an outsized impact on the future of medicine.
